Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002  by Sawabata, Noriyoshi et al.
ORIGINAL ARTICLE
Japanese Lung Cancer Registry Study
First Prospective Enrollment of a Large Number of Surgical and
Nonsurgical Cases in 2002
Noriyoshi Sawabata, MD, PhD,* Hisao Asamura, MD, PhD,† Tomoyuki Goya, MD, PhD,‡
Masaki Mori, MD, PhD,§ Yoichi Nakanishi, MD, PhD, Kenji Eguchi, MD, PhD,¶
Yoshihiko Koshiishi, MD, PhD,‡ Meinoshin Okumura, MD, PhD,* Etsuo Miyaoka, PhD,#
and Yoshitaka Fujii, MD, PhD**; for the Japanese Joint Committee for Lung Cancer Registry
Purpose: To investigate prognoses of lung cancer patients prospec-
tively enrolled in the Japan Lung Cancer Registry Study.
Methods: Patients newly diagnosed as having lung cancer exclu-
sively in 2002 were enrolled. Follow-up surveys were performed
twice, in 2004 and 2009, and the final follow-up data with
prognoses were analyzed for 14,695 patients (79%). Clinical
stages were defined according to the sixth edition of the Interna-
tional Union Against Cancer-tumor, node, metastasis classifica-
tion (2002).
Results: The mean age was 67.1 years (range, 18–89 years), and there
were 10,194 men (69.3%) and 4315 women (29.7%). The most fre-
quent histology was adenocarcinoma (n  8325, 56.7%), followed by
squamous cell carcinoma (n  3778, 26%) and small cell carcinoma
(n 1345, 9.2%). The distribution of clinical stages was as follows: IA,
4245 cases (29.3%); IB, 2248 (14.5%); IIA, 208 (1.4%); IIB, 918
(6.3%); IIIA, 1700 (11.8%); IIIB, 2110 (16.3%); and IV, 3037 (21.0%).
The 5-year survival rates were 44.3% for all patients, 46.8% for those
with non-small cell lung cancer, and 14.7% for those with small cell
lung cancer. According to the clinical stage of non-small cell lung
cancer and small cell lung cancer, the 5-year survival rates were 79.4
and 52.7% for stage IA, 56.9 and 39.3% for IB, 49.0 and 31.7% for IIA,
42.3 and 29.9% for IIB, 30.9 and 17.2% for IIIA, 16.7 and 12.4% for
IIIB, and 5.8 and 3.8% for IV, respectively.
Conclusion: Analysis of a large cohort in the Japanese registry
study found that stage-specific prognosis was within a range similar
to other reports. The data presented should provide an important
reference for future clinical trials in Japan.
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(J Thorac Oncol. 2010;5: 1369–1375)
In Japan, nationwide registration of surgically treated lungcancer patients has been conducted three times, in 1994,
1999, and 2004, for cases surgically treated in 1989, 1994,
and 1999, respectively. The latter two registrations were
conducted by the Japanese Joint Committee for Lung Cancer
Registry, which was established in 1998, and their results
have been published.1–2 In 1999, the number of cases regis-
tered increased to 7393 from the 3643 registered in 1994,3,4
whereas those registered in 2004 further increased to 13,340.
Currentaly, the Japanese Joint Committee for Lung Cancer
Registry is jointly coordinated by three associations, the
Japanese Respiratory Society, the Japanese Lung Cancer
Society, and the Japanese Association for Chest Surgery.
The three registry studies noted earlier were retrospective
surveys of patients who were resected 5 years earlier. Data from
the latest study performed in 20042 were used by the staging
project of the International Association for Study of Lung
Cancer (IASLC) and contained 7393 Japanese cases, which
represented 9.1% of all cases subjected to analysis. Cases from
North America, Europe, and Australia consisted of a greater
percentage of nonsurgical cases with more advanced stages
compared with the cases from the Japanese Joint Committee for
Lung Cancer Registry, which were mainly surgical cases and
earlier stages. The efforts of the IASLC staging committee have
resulted in a number of published studies, including one in
2007,5 all of which led to the proposal of tumor, node, metastasis
(TNM) staging in the seventh edition of the International Union
Against Cancer (UICC).6,7 Results of more detailed analyses of
the data obtained in the 2004 survey conducted by the Japanese
Joint Committee for Lung Cancer Registry have also been
published.8,9 However, because those studies were retrospective
and consisted of only surgically treated patients, they were
biased toward earlier stage and non-small cell lung cancer
(NSCLC) cases. As a result, prospective enrollment including
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nonsurgical cases representing a large, nonbiased number of
lung cancer patients was considered necessary.
Herein, the Japanese Joint Committee for Lung Cancer
Registry reports the demographics and survival of 14,695
Japanese patients with lung cancer who were diagnosed and
prospectively enrolled in 2002.
PATIENTS AND METHODS
The Japanese Joint Committee for Lung Cancer Registry
conducted a prospective observational study of patients who
were first diagnosed as having primary lung cancer exclusively
in 2002. The committee asked 570 teaching hospitals in Japan to
participate in the study; 358 (63%) participated in the program.
Inclusion criteria were as follows: (1) pathologically (including
cytology) diagnosed as any lung cancer at an institute; (2)
exclusively in 2002; and (3) regardless of treatment modality
(including supportive care alone). Patients with lung cancer
recurrence, metastasis, or double cancer were excluded. Nine
variables were recorded at the time of registration in 2002: (1)
sex, (2) age, (3) date of diagnosis, (4) performance status (PS),
(5) clinical stage, (6) clinical T factor, (7) clinical N factor, (8)
clinical M factor, and (9) histologic subtype of lung cancer. Two
years later in 2004, treatment modalities and prognoses were
reported for these cases. In 2009, the following 20 points were
investigated for all surgical cases: (1) type of operation, (2)
extent of lymph node resection, (3) radicality of resection, (4)
residual tumor, (5) location of tumor, (6) tumor size, (7) tumor
histology, (8) invaded organ, (9) pleural invasion, (10) pleural
dissemination, (11) pulmonary metastasis, (12) cytology of pleu-
ral effusion, (13) pathologic stage, (14) pathologic T factor, (15)
pathologic N factor, (16) pathologic M factor, (17) lymph node
metastasis, (18) survival period, (19) presence or absence of
recurrence, and (20) cause of death. For cases that did not
undergo surgery, survival period, recurrence, and cause of death
were reported. All patients were staged clinically according to
the sixth version of the UICC-TNM classification.10 Because the
TABLE 1. Patients’ Background Characteristics
Total Surgery No Surgery
Missing
Data
n 14,695 8454 (57.5%) 5735 (39.0%) 506 (3.5%)
Gender
Male 10,194 5457 4349 388
Female 4315 2878 1322 115
Missing value 186 (1.3%) 119 64 3
Age (yr),
meanSD
67.1  10.1 66.4  9.9 68.2  10.4
PS
0 8714 6827 1717 170
1 4076 1364 2460 252
2 1077 192 837 48
3 516 40 453 23
4 240 3 226 11
Missing value 72 (0.5%) 28 42 2
Treatment
Pre-OP CTxa 395
Pre-OP RTxa 180
Post-OP CTxa 1749
Post-OP RTxa 624
CTx 2575
RTx 684
CTx  RTx 1300
SC 1162
Missing value 14 (0.2%)
a Redundancy permitted.
SD, standard deviation; PS, performance status; OP, operation; CTx, chemotherapy;
RTx, radiotherapy; SC, supportive care.
TABLE 2. Tumor Characteristics
Total Surgery No Surgery
Missing
Data
n 14,695 8454 (57.5%) 5735 (39.0%) 506 (3.5%)
c-Stage
0 38 28 9 1
IA 4245 4029 174 42
IB 2248 2009 206 33
IIA 208 152 51 5
IIB 918 709 184 25
IIIA 1700 919 707 74
IIIB 2110 357 1621 132
IV 3037 169 2687 181
Occult 5 0 4 1
Missing value 186 (1.3%) 82 92 12
cT
0 47 25 18 4
1 5135 4422 629 84
2 4985 3045 1783 157
3 1286 578 668 40
4 3154 360 2578 216
Tis 12 6 6 0
Tx 43 7 32 4
Missing value 33 (0.2%) 11 21 1
cN
0 7925 6647 1134 144
1 1332 751 536 45
2 3491 959 2333 199
3 1908 87 1704 117
Missing value 39 (0.3%) 10 28 1
cM
0 11,536 8247 2971 318
1 3099 188 2725 186
Missing value 60 (0.4%) 19 39 2
Histology
SM 1345 165 1104 76
AD 8325 5463 2643 219
SQ 3778 2151 1506 121
ADSQ 116 76 38 2
LA 439 211 186 42
Other 485 222 256 7
Missing value 207 (1.4%) 166 2 39
c-Stage, clinical stage; cT, clinical T factor; Tis, carcinoma in situ; Tx, primary
carcinoma cannot be assessed; cN, clinical N factor; cM, clinical M factor; SM, small
cell carcinoma; AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adeno-
squamous cell carcinoma; LA, large cell carcinoma.
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registry included nonsurgical patients, analyses in this report
were carried out using clinical stage.
This registry was approved by the Institutional Review
Boards of Kyorin Medical University Hospital (former reg-
istration office) and Osaka University Graduate School of
Medicine (current registration office).
In 2002, 18,552 cases of primary lung cancer were registered
from 358 institutions, with treatment modalities and survival re-
corded in the survey conducted in 2004. Additional survival data
were available for 10,183 of these cases (55%) from the survey
conducted in 2009. As a result, survival was analyzed for a total
of 14,695 cases (79%), for which survival data were available.
FIGURE 1. A and B, Survival curves
by histology. The 5-year survival
rates for NSCLC and SCLC are
46.8% and 14.7%, respectively. The
5-year survival rates and p values are
shown in Table 4. NSCLC, non-small
cell lung cancer; SCLC, small cell
lung cancer; AD, adenocarcinoma;
SQ, squamous cell carcinoma;
ADSQ, adenosquamous cell carci-
noma; LA, large cell carcinoma.
TABLE 3. Patients’ Characteristics by Histology
Non-small Cell Carcinoma
Small Cell
CarcinomaAD SQ ADSQ LA Total
n 8325 3778 116 439 12,658 1345
Gender
Male 4742 3334 82 372 8530 1122
Female 3469 400 32 61 3962 209
Missing value 114 44 2 6 166 14
Age (yr), mean  SD 65.7  10.6 69.6  8.6 67.8  10.2 65.3  10.7 67.0  10.1 68.7  9.2
PS
0 5556 2024 68 223 7871 471
1 1925 1222 37 149 3333 549
2 447 332 8 33 820 170
3 215 132 3 24 374 109
4 114 60 0 9 183 36
Missing value 68 8 0 1 77 10
c-Stage
IA 3239 686 29 57 4011 96
IB 1301 712 30 52 2095 57
IIA 85 88 1 3 177 20
IIB 355 434 9 40 838 40
IIIA 684 670 11 72 1437 221
IIIB 901 656 18 92 1667 356
IV 1685 523 18 118 2344 533
Missing value 75 9 0 5 89 22
Treatment
Surgery 5463 2151 76 211 7901 165
No surgery 2643 1506 38 186 4373 1088
CTx 1275 514 18 72 1879 607
RTx 262 309 2 24 597 37
CTx  RTx 472 372 11 42 897 359
SC 634 311 7 48 1000 85
Missing value 219 121 2 42 384 92
c-Stage, clinical stage; AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous cell carcinoma; LA, large cell
carcinoma; SD, standard deviation; PS, performance status; CTx, chemotherapy; RTx, radiotherapy; SC, supportive care.
Journal of Thoracic Oncology • Volume 5, Number 9, September 2010 Japanese Lung Cancer Registry Study
Copyright © 2010 by the International Association for the Study of Lung Cancer 1371
The survival period was defined as the time between the
dates of diagnosis and latest follow-up. Survival curves were
estimated according to the Kaplan-Meier method for subsets
such as clinical stage, sex, histologic subtype of tumor, treatment
modality, and PS. Differences between survival rates were
evaluated using the log-rank method. Multivariate analyses were
performed with a Cox proportional hazards model to identify
patient characteristics. Clinical stage, sex, histologic subtype,
treatment modality, and PS were entered as variables. The
pathologic stages of surgical patients were revealed at the survey
in 2009, and survival analyses by pathologic stage were carried
out exclusively in surgical patients. Because the rate of missing
data was less than 3.5%, statistical analyses were performed
after excluding cases with missing values for relevant variables.
A p value of less than 0.05 was considered statistically significant.
FIGURE 2. Clinical stage-specific
survival curves for patients with (A)
non-small cell carcinoma and (B)
small cell carcinoma, by clinical
stage. The 5-year survival rates and
p values are shown in Table 5.
TABLE 4. Survival by Histology
Histology
AD SQ ADSQ LA SM
n (%) 8325 (64.1) 3778 (29.1) 116 (0.9) 439 (3.4) 1345 (10.4)
5-Year survival
rate (%)
53.2 36.5 35.5 27.7 14.7
p
AD 0.0001 0.0001 0.001 0.0001
SQ 0.0001 0.8 0.0001
ADSQ 0.003 0.0001
LA 0.0001
AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous cell
carcinoma; LA, large cell carcinoma; SM, small cell carcinoma.
TABLE 5. Clinical Stage-Specific Survival
Histology Total
c-Stage
IA IB IIA IIB IIIA IIIB IV
Non-small cell carcinoma
n (%) 12,993 (100)a 4020 (31) 2133 (16.4) 184 (1.4) 860 (6.6) 1441 (11.1) 1714 (13.2) 2447 (18.8)
5-Year survival rate (%) 46.8 79.4 56.9 49 42.3 30.9 16.7 5.8
p
IA 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
IB 0.003 0.0001 0.0001 0.0001 0.0001
IIA 0.2 0.0001 0.0001 0.0001
IIB 0.0001 0.0001 0.0001
IIIA 0.0001 0.0001
IIIB 0.0001
Small cell carcinoma
n (%) 1323 (100)b 96 (7.3) 57 (4.3) 20 (1.5) 40 (3) 221 (16.7) 356 (26.9) 533 (40.3)
5-Year survival rate (%) 14.7 52.7 39.3 31.7 29.9 17.2 12.4 3.8
p
IA 0.4 0.3 0.004 0.0001 0.0001 0.0001
IB 0.8 0.2 0.004 0.0001 0.0001
IIA 0.1 0.1 0.006 0.0001
IIB 0.0001 0.0001 0.0001
IIIA 0.0006 0.0001
IIIB 0.0001
a Includes histology type other than adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, and large cell carcinoma.
b Excludes missing data.
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RESULTS
The characteristics of the 14,695 patients are shown in
Table 1. Because the form used in 2004 (2 years after the first
registration) required the dichotomous choice of surgery or no
surgery, the backgrounds of patients both with and without
surgery are also shown. The mean age was 67.1 years (range,
18–98 years), and there were 10,194 men (70.3%) and 4315
women (29.7%). The majority (87%) of patients had a good PS
score (0 or 1).
Tumor characteristics are shown in Table 2. The most
frequent clinical stage was IA (29.3%) followed by IV (21.0%),
IB (14.5%), IIIB (16.3%), IIIA (11.8%), IIB (6.3%), and IIA
(1.4%). Of the patients undergoing surgery, 85% were staged as
clinical I or II. In addition, 34% of the surgical cases received
adjuvant therapy. In contrast, of the nonsurgical patients, 40%
were staged as clinical III, and 47% were staged as clinical IV.
As for histologic type, adenocarcinoma was the most
common (56.7%), followed by squamous cell carcinoma
(25.7%) and small cell carcinoma (9.2%). Characteristics by
histologic type are shown in Table 3. Sex distribution was
significantly different for adenocarcinoma and squamous cell
carcinoma. Overall, 83% of women and 47.6% of men had
adenocarcinomas, which was in contrast to squamous cell car-
cinomas, which were noted in 33.5% of men and only 10.0% of
women.
The 5-year survival rate (5YSR) for the entire group of
patients was 44.3%. For women, the survival rates at 1, 2, 3, 4,
and 5 years are 82.8, 77.3, 66.2, 62.0, and 59.0%, respectively,
whereas survival rates for men are 69.2, 53.6, 45.5, 40.9, and
37.7%, respectively, which shows that women had superior
survival. Survival curves by major histologic type are shown in
Figure 1, and 5YSRs are shown in Table 4. The 5YSR was
14.7% for small cell carcinoma and 46.8% for non-small cell
carcinoma. Patients with adenocarcinoma had a 5YSR of 53.2%,
which was markedly better than that for those with squamous
cell carcinoma (36.5%) or adenosquamous carcinoma (35.5%).
Small cell carcinoma cases had very poor survival (14.7%).
According to the clinical stages of NSCLC and small cell
lung cancer (SCLC; Figure 2 and Table 5), the 5YSRs were 79.4
and 52.7% for stage IA, 56.9 and 39.3% for IB, 49.0 and 31.7%
for IIA, 42.3 and 29.9% for IIB, 30.9 and 17.2% for IIIA,
16.7and 12.4% for IIIB, and 5.8 and 3.8% for IV, respectively.
Survival by treatment modality is shown in Figure 3 and Table
6. The 5YSRs were 66.0and 8.5% for surgical and nonsurgical
cases, respectively. In the nonsurgical cases, chemotherapy plus
radiation therapy provided the best survival, whereas those who
received only supportive care (including chest drainage and
pleurodesis) had the worst survival. Survival by PS is shown in
Table 7; those with poor PS had a poor prognosis.
Results of multivariate analyses are shown for NSCLC
in Table 8 and for SCLC in Table 9. Clinical stage, sex,
histologic subtype, treatment modality, and PS were entered
as variables. Analysis of NSCLC showed that clinical stage,
sex, histology, treatment, and PS were all independent sig-
nificant prognostic factors. In contrast, in the analysis of
SCLC, advanced clinical stage (III or IV), sex, chemotherapy
alone or radiotherapy alone, and PS were independent prog-
nostic factors.
FIGURE 3. A and B, Survival curves
by treatment. The 5-year survival
rates for surgical and nonsurgical
cases are 66.0% and 8.5%, respec-
tively. The 5-year survival rates and
p values are shown in Table 6. CTx,
chemotherapy; RTx, radiotherapy;
SC, supportive care including chest
drainage and pleurodesis.
TABLE 6. Survival by Treatment
Treatment
Surgery
No Surgery
CTx RTx CTx  RTx SC
n (%) 8454 (57.4) 2575 (17.6) 684 (4.7) 1300 (8.9) 1162 (7.9)
5-Year survival rate (%) 66 6.5 13.3 13.3 4.3
p
Surgery 0.0001 0.0001 0.0001 0.0001
CTx 0.1 0.0001 0.0001
RTx 0.0001 0.0001
CTx  RTx 0.0001
CTx, chemotherapy; RTx, radiotherapy; SC, supportive care.
Journal of Thoracic Oncology • Volume 5, Number 9, September 2010 Japanese Lung Cancer Registry Study
Copyright © 2010 by the International Association for the Study of Lung Cancer 1373
Survivals for surgical cases by pathologic stage are
shown in Table 10 and Figure 4. The 5YSR for pathologic
stage IA was 89.3%. In advanced pathologic stages, the
5YSRs were 46.8% for pathologic stage IIIA, 53.0% for IIIB,
and 41.0% for IV.
DISCUSSION
A large cohort of Japanese patients with lung cancer
who were registered in 2002 and followed up was analyzed.
This population differs from the cohorts of former Japanese
registries; former Japanese registries included cohorts of only
surgical cases. This registry included nonbiased patients who
underwent surgery, chemotherapy, radiotherapy, a combina-
FIGURE 4. Stage-specific survival curves for surgical cases
by pathologic stage. The 5-year survival rates and p values
are shown in Table 10.
TABLE 7. Survival by Performance Status
Performance Status
0 1 2 3 4
n (%) 8714 (59.6) 4076 (27.9) 1077 (7.4) 516 (3.5) 240 (1.6)
5-Year survival
rate (%)
59.3 24 13.7 5.6 3.1
p
0 0.0000 0.0000 0.0000 0.0000
1 0.0000 0.0000 0.0000
2 0.0000 0.0000
3 0.0000
TABLE 8. Multivariate Analysis of Non-small Cell Lung
Cancer
Variable Relative Risk 95% CI p
c-Stage
IA Reference
IB 2.196 1.978–2.437 0.0001
IIA 2.412 1.899–3.063 0.0001
IIB 2.966 2.612–3.369 0.0001
IIIA 3.475 3.112–3.880 0.0001
IIIB 3.736 3.326–4.195 0.0001
IV 5.179 4.615–5.813 0.0001
Gender
Female Reference
Male 1.504 1.408–1.607 0.0001
Histology
AD Reference
SQ 1.168 1.097–1.242 0.0001
LA 1.478 1.295–1.686 0.0001
ADSQ 1.407 1.087–1.821 0.01
Treatment
Surgery Reference
No surgery
CTx 2.566 2.331–2.825 0.0001
RTx 2.516 2.224–2.847 0.0001
CTx  RTx 1.964 1.763–2.187 0.0001
SC 4.69 4.193–5.246 0.0001
PS
0 Reference
1 1.362 1.275–1.455 0.0001
2 1.953 1.768–2.158 0.0001
3 2.795 2.441–3.201 0.0001
4 3.765 3.126–4.534 0.0001
AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous cell
carcinoma; LA, large cell carcinoma; c-Stage, clinical stage; CTx, chemotherapy; RTx,
radiotherapy; SC, supportive care; PS, performance status.
TABLE 9. Multivariate Analysis of Small Cell Lung Cancer
Variable Relative Risk 95% CI p
c-Stage
IA Reference
IB 1.082 0.644–1.817 0.8
IIA 1.324 0.641–2.737 0.5
IIB 1.649 0.977–2.785 0.06
IIIA 1.807 1.204–2.713 0.004
IIIB 2.285 1.514–3.448 0.0001
IV 2.791 1.859–4.190 0.0001
Gender
Female Reference
Male 1.321 1.094–1.595 0.004
Treatment
Surgery Reference
No surgery
CTx 2.481 2.267–2.714 0.005
RTx 2.530 2.248–2.847 0.0001
CTx  RTx 1.824 1.654–2.013 0.6
SC 4.828 4.345–5.365 0.0001
PS
0 Reference
1 1.217 1.034–1.432 0.020
2 1.551 1.236–1.947 0.0001
3 3.270 2.530–4.226 0.0001
4 2.143 1.423–3.228 0.0001
c-Stage, clinical stage; CTx, chemotherapy; RTx, radiotherapy; SC, supportive
care; PS, performance status.
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tion of these modalities, or supportive care. This is the first
prospective registry in Japan, and the results present a selec-
tion of the patterns of practice and outcomes at a fraction of
the teaching hospitals in the country.
For survival analysis, 14,695 cases, including 8454 surgi-
cal and 5735 nonsurgical cases, were analyzed using survival
data obtained in 2004 and updated in the 2009 survey. The rate
of missing data was at most 3.5%, lower than the rate of missing
data in the staging project of the IASLC 2009; the rate of
incomplete stage information was 8.0%11 in the IASLC project.
Patients who underwent surgery had quite a different
background from those who were treated without surgery, be-
cause (1) the mean age of surgical cases was 2 years younger
than that of nonsurgical cases, (2) the dominant majority of PS
scores was 0 or 1 in surgical cases, whereas 30% of the
nonsurgical cases were at PS 2 or more, (3) clinical stage was I
or II in 80% of the surgical cases and in only about 10% of the
nonsurgical cases, and (4) small cell carcinoma represented 2%
of the surgical and 19% of the nonsurgical cases.
Based on the UICC-TNM sixth edition classification
(2002),10 each clinical stage of NSCLC had a significantly
different rate of survival from its neighboring stage, except
for clinical stages IIA and IIB. The same finding was reported
in a previous Japanese registry of surgical patients.1
In pathologic stages using variable data based on the 2009
survey, the 5YSRs for pathologic stages IIIA, IIIB, and IV were
46.8, 53.0, and 41.0%, respectively. These rates were much
higher than expected, which might be attributed to the high rate
(60%) of clinical nonadvanced stages (clinical stage I, 46%; and
clinical stage II, 24%) among patients whose pathologic stages
were defined. It has been reported that among cases with
pathologic advanced stages, those who were diagnosed as a
nonadvanced clinical stage showed a better prognosis than those
who were diagnosed as an advanced clinical stage.12
Although this registration program was conducted in a
prospective setting in an accrual manner, the follow-up find-
ings were retrospective; thus, 21% of the patients were lost to
follow-up in 2004 and 45% in 2009. Therefore, the accuracy
of the prognoses may be limited in ths current analyses.
Because a large number of patients treated with both surgical
and nonsurgical modalities was prospectively accrued, the
data presented here should provide an important reference for
future clinical trials in Japan.
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n (%) 4170 (100) 1926 (46.2) 962 (23.1) 132 (3.2) 370 (8.9) 444 (10.6) 277 (6.6) 59 (1.4)
5-Year survival
rate (%)
89.3 74.5 71.4 64.3 46.8 53.0 41.0
p
IA 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
IB 0.7 0.0001 0.0001 0.0001 0.0001
IIA 0.03 0.0001 0.0002 0.0002
IIB 0.0001 0.01 0.02
IIIA 0.1 0.9
IIIB 0.5
p-Stage, pathologic stage; UICC, International Union Against Cancer; TNM, tumor, node, metastasis.
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